Noguchi, Saki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬剤学講座 (Shiba-Kyoritsu)

Position

Research Associate/Assistant Professor/Instructor

Academic Degrees 【 Display / hide

  • Ph.D.(Pharmacy), Keio University, Coursework, 2017.03

 

Papers 【 Display / hide

  • Quantification of ENT1 and ENT2 Proteins at the Placental Barrier and Contribution of These Transporters to Ribavirin Uptake

    Nishimura T., Sano Y., Takahashi Y., Noguchi S., Uchida Y., Takagi A., Tanaka T., Katakura S., Nakashima E., Tachikawa M., Maruyama T., Terasaki T., Tomi M.

    Journal of Pharmaceutical Sciences (Journal of Pharmaceutical Sciences)  108 ( 12 ) 3917 - 3922 2019.12

    ISSN  00223549

     View Summary

    © 2019 The Authors The aims of this study are to quantify the protein levels of nucleoside transporters in placental microvillous membranes (MVMs) and to clarify the contributions of these transporters to ribavirin uptake at the placental barrier. Placental MVMs of human and rat expressed equilibrative nucleoside transporter (ENT) 1 protein, whereas the expression of ENT2 protein was obscure. Maternal-to-fetal transfer of [3H]ribavirin in rats was much higher than that of [14C]sucrose. The uptake of [3H]ribavirin by rat placental trophoblast TR-TBT 18 d-1 cells, which functionally express both ENT1 and ENT2 proteins, was saturable, and was significantly inhibited by 0.1 μM nitrobenzylthioinosine, which selectively abolishes ENT1-mediated uptake. Dipyridamole at 10 μM is capable of inhibiting ENT2 as well as ENT1, but a degree of inhibition by 10 μM dipyridamole on [3H]ribavirin uptake was not much different from that by 0.1 μM nitrobenzylthioinosine (ENT1-specific inhibitor). Therefore, ENT2 may contribute little to [3H]ribavirin uptake by these cells. Rat ENT1 cRNA-injected oocytes showed increased [3H]ribavirin uptake compared with water-injected oocytes, while rat ENT2 cRNA-injected oocytes did not. In conclusion, ENT1 protein expressed in placental MVMs appears to play a predominant role in the uptake of ribavirin.

  • Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line.

    Yu Takahashi, Tomohiro Nishimura, Kei Higuchi, Saki Noguchi, Yuma Tega, Toshiki Kurosawa, Yoshiharu Deguchi, Masatoshi Tomi

    Pharmaceutical Research (Pharmaceutical Research)  35 ( 12 ) 246 2018.10

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  07248741

     View Summary

    © 2018, The Author(s). Purpose: The anti-epileptic drug pregabalin crosses the blood-brain barrier (BBB) in spite of its low lipophilicity. This study was performed to determine whether L-type amino acid transporters (LAT1/SLC7A5 and LAT2/SLC7A8) contribute to the uptake of pregabalin. Methods: Pregabalin uptake by LATs-transfected HEK293 cells or hCMEC/D3 cells, an in vitro human BBB model, was measured by LC-MS/MS analysis. Expression of LAT1 mRNA in hCMEC/D3 cells was determined by quantitative RT-PCR analysis. Results: Overexpression of LAT1, but not LAT2, in HEK293 cells significantly increased the cellular uptake of pregabalin, and the LAT1-mediated uptake was saturable with a Km of 0.288 mM. LAT1-mediated amino acid uptake was inhibited specifically and almost completely in the presence of 1 mM pregabalin. The uptake of pregabalin by hCMEC/D3 cells was sodium-independent, saturable (Km = 0.854 mM), and strongly inhibited by large amino acids at 1 mM, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid, a specific system L inhibitor, at 1 mM and by JPH203, a LAT1-selective inhibitor, at 10 μM. Pregabalin uptake in hCMEC/D3 cells was also decreased by 75% by the silencing of LAT1 gene using LAT1 siRNA. Conclusions: Our results indicate that LAT1, but not LAT2, recognizes pregabalin as a substrate. It is suggested that LAT1 mediates pregabalin transport at the BBB.

  • Cellular Uptake of Levocetirizine by Organic Anion Transporter 4

    Saki Noguchi, Tomohiro Nishimura, Saya Mukaida, Leslie Z. Benet, Emi Nakashima, Masatoshi Tomi

    Journal of Pharmaceutical Sciences 106 ( 9 ) 2895 - 2898 2017.09

    Research paper (scientific journal), Accepted

  • Organic Anion Transporter 4-Mediated Transport of Olmesartan at Basal Plasma Membrane of Human Placental Barrier

    Noguchi Saki, Nishimura Tomohiro, Fujibayashi Ayasa, Maruyama Tetsuo, Tomi Masatoshi, Nakashima Emi

    Journal of Pharmaceutical Sciences 104 ( 9 ) 3128 - 3135 2015.09

    Research paper (scientific journal)

  • Role of protein kinase A in regulating steroid sulfate uptake for estrogen production in human placental choriocarcinoma cells,

    Tomi Masatoshi, Miyata Yuki, Noguchi Saki, Nishimura Sachika, Nishimura Tomohiro, Nakashima Emi

    Placenta 35 ( 8 ) 658 - 660 2014.08

    Research paper (scientific journal),  ISSN  0143-4004

Papers, etc., Registered in KOARA 【 Display / hide

Presentations 【 Display / hide

  • ヒト絨毛癌由来JEG-3細胞の分化過程におけるmiR-126発現がLIN28A発現に与える影響

    潘晓乐、野口幸希、安藤美鈴、竹村 千尋、西村友宏、登美斉俊

    第3回トランスポーター研究会関東部会 (千葉) , 2018.11

  • マウス胎盤細胞膜MDR1およびBCRPタンパクの妊娠進行に伴う発現量推移

    植田 有美、西村 友宏、野口 幸希、明石 知也、立川 正憲、内田 康雄、寺崎 哲也、登美 斉俊

    第3回トランスポーター研究会関東部会 (千葉) , 2018.11

  • 血液脳関門における中性アミノ酸トランスポーターLAT1 を介したpregabalin輸送

    高橋優、西村友宏、樋口慧、野口幸希、手賀悠真、黒澤俊樹、 出口芳春、登美斉俊

    第40回生体膜と薬物の相互作用シンポジウム (仙台) , 2018.10

  • Lower fetal toxicity and transfer of irbesartan compared to olmesartan in rats

    Ishikawa Y, Nishimura T, Noguchi S, Tomi M

    2018 MDO/JSSX /日本薬物動態学会第33年会 (Kanazawa, Japan) , 2018.10

  • Mother-to-Fetal Transfer of HMG-CoA Reductase Inhibitors in Pregnant Rats

    Nishimura T, Yonemura N, Noguchi S, Tomi M

    2018 MDO/JSSX /日本薬物動態学会第33年会 (Kanazawa, Japan) , 2018.10

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 胎盤合胞体化と内分泌機能の成熟制御機構を標的とした妊娠合併症治療戦略

    2018.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 野口 幸希, Grant-in-Aid for Early-Career Scientists , Principal Investigator

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD: (PHARMACEUTICS)

    2020

  • SPECIAL PRACTICE IN TISSUE CULTURE AND GENE TECHNOLOGY

    2020

  • SEMINAR: (PHARMACEUTICS)

    2020

  • RESEARCH FOR BACHELOR'S THESIS 1

    2020

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2020

display all >>